Literature DB >> 1935458

Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas.

O Mørkve1, O D Laerum.   

Abstract

The nuclear protein p53 has been measured in archival lung cancer biopsies. The monoclonal antibody PAb 1801, which recognizes human p53, was used. After immunostaining, the nuclei prepared from paraffin-embedded tissue were stained with propidium iodide for simultaneous measurement of DNA content; 17 of 24 lung cancers were p53 positive. The S-phase fraction in positive tumors was 22.9 +/- 6.4%, as compared to 13.6 +/- 6.1% in negative tumors (P less than 0.02). In ten of the positive tumors (two small cell carcinomas and eight non-small cell carcinomas), the p53 expression varied through cell cycle, whereas in seven tumors (five small cell carcinomas and two non-small cell carcinomas), no such variation of p53 expression was observed. Freezing the nuclear suspensions did not substantially reduce the p53 signals. Control experiments with the SV40-transformed human foreskin fibroblast cell line HSF4-T12 showed that the enzymatic digestion utilized to dissociate paraffin-embedded tissue did not significantly reduce p53 fluorescence. Immunohistochemical staining of biopsy specimens indicated that only cancer cells were overexpressing p53. In conclusion, using the monoclonal antibody PAb 1801, p53 is detectable in cell nuclei prepared from paraffin-embedded bronchial carcinoma biopsies. P53 positive tumors have increased proliferative activity compared to p53 negative tumors. Furthermore, the lack of cell cycle variation of p53 in small cell carcinomas indicates that this pattern may be related to high-grade malignancy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1935458     DOI: 10.1002/cyto.990120509

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  8 in total

1.  Tumour fragment spheroids from human non-small-cell lung cancer maintained in organ culture.

Authors:  L Fjellbirkeland; R Bjerkvig; O D Laerum
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

2.  Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.

Authors:  G Sauter; G Deng; H Moch; R Kerschmann; K Matsumura; S De Vries; T George; J Fuentes; P Carroll; M J Mihatsch
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

3.  p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer.

Authors:  H Moch; G Sauter; D Moore; M J Mihatsch; F Gudat; F Waldman
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

4.  Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas.

Authors:  W Domagala; B Harezga; A Szadowska; M Markiewski; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

5.  The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg 2.2.15.

Authors:  Hai Bin He; Xian Lin Wu; Bin Yu; Kang Li Liu; Guang Xiong Zhou; Guo Qiang Qian; Da Hong Ju; Xiao Yin Chen
Journal:  Hepat Mon       Date:  2011-05       Impact factor: 0.660

6.  p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.

Authors:  B Wadayama; J Toguchida; T Yamaguchi; M S Sasaki; T Yamamuro
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

7.  The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma.

Authors:  B V Joypaul; D Hopwood; E L Newman; S Qureshi; A Grant; S A Ogston; D P Lane; A Cuschieri
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

8.  Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer.

Authors:  S D Fosså; A A Berner; A B Jacobsen; H Waehre; B Kvarstein; T Urnes; P Ogreid; T E Johansen; J Silde; J M Nesland
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.